Interchangeability of blood culture bottles and automats for blood culture systems: an in-vitro performance evaluation

The Lancet Microbe · Published 2026-07-01 · DOI 10.1016/j.lanmic.2026.101438

Free full text

Authors (5)

Anke Breine, Tine Vermoesen, Ellen Corsmit, Els Genbrugge, Liselotte Hardy

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Breine, A., Vermoesen, T., Corsmit, E., et al. (2026). Interchangeability of blood culture bottles and automats for blood culture systems: an in-vitro performance evaluation. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2026.101438

Related articles

• VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial · The Lancet Microbe · 2026 · Same journal
• ESCMID Global Congress 2026 · The Lancet Microbe · 2026 · Same journal
• Context-dependent and ecological drivers of neonatal invasive Escherichia coli population dynamics—Authors’ reply · The Lancet Microbe · 2026 · Same journal
• The hantavirus question we are not asking · The Lancet Microbe · 2026 · Same journal
• Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial · The Lancet Microbe · 2026 · Same journal
• Genotype-based antimicrobial resistance tests need a new regulatory framework · The Lancet Microbe · 2026 · Same journal
• Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study · The Lancet Microbe · 2026 · Same journal
• Strengthening pre-spillover surveillance: the missing link in Ebola preparedness · The Lancet Microbe · 2026 · Same journal
• Andes virus induces a chemokine-dominant endothelial and stromal activation pattern that promotes immune-cell recruitment · The Lancet Microbe · 2026 · Same journal
• Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial · The Lancet Microbe · 2026 · Same journal